IOVA, US4622601007

Iovance Biotherapeutics stock targets 2027 lung cancer filing

Published on 11/17/2026 at 22:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Iovance Biotherapeutics stock faces a 2027 lung cancer filing and a 9% AMTAGVI increase. 2026 revenue guidance remains $410 million to $420 million.

Growth plans and commercial targets

  • Iovance expects to seek a broad second-line lung cancer indication for AMTAGVI in 2027.
  • AMTAGVI and PROLEUKIN generated about $122 million in third-quarter U.S. sales, while year-to-date revenue reached $292 million.
  • The company is targeting at least 110 AMTAGVI treatment centers by year-end and plans price increases effective January 1, 2027.
IOVA, US4622601007, Illustration mit AI erstellt.

Iovance Biotherapeutics said at a Jefferies event on Monday, November 16, that it expects to seek a broad second-line lung cancer indication for AMTAGVI in 2027. The company is nearing completion of enrollment in its 80-patient IOV-LUN-202 registrational trial and plans to present a fuller data set at a major medical meeting, according to MarketBeat.

Lung cancer filing plans advance

An updated analysis cited at the event showed a 25% overall response rate among 69 patients. Iovance said response rates had remained consistent across data cuts, while duration-of-response data remained too immature for assessment.

The company is also pursuing the POSITILITY cohort for a biomarker-defined subgroup and plans to start the first-line OPTILISM lung study in 2027. A potential filing for the subgroup would follow the broader lung cancer application.

Sales and pricing support growth

AMTAGVI and PROLEUKIN generated about $122 million in third-quarter U.S. sales, bringing Iovance's year-to-date revenue to $292 million. Management cited 2026 revenue guidance of $410 million to $420 million and said the company was on track to reach at least 110 authorized AMTAGVI treatment centers by year-end.

Iovance plans to raise AMTAGVI's price by 9% and PROLEUKIN's price by 7% effective January 1, 2027. The company is also advancing studies in earlier-stage melanoma and soft-tissue sarcoma.

Iovance Biotherapeutics stock traded at 6.86 euros on Lang & Schwarz at 22:34 CET on Tuesday, November 17, 2026.

Iovance Biotherapeutics

  • Company: Iovance Biotherapeutics, Inc.
  • ISIN: US4622601007
  • Ticker: IOVA
  • Home exchange: Nasdaq
  • Lang & Schwarz price: 6.86 euros at 22:34 CET on November 17, 2026

The S&P 500 provides the broader U.S. market backdrop for Iovance Biotherapeutics stock.

More news and analyses on Iovance Biotherapeutics stock

Disclaimer...
en | US4622601007 | IOVA | boerse | 70528756 | bgmi